Targeting the Hippo/YAP Pathway: A Promising Approach for Cancer Therapy and Beyond

Abstract

Cancer represents a growing cause of death and a threat to public health worldwide; thus, there is an urgent need to understand its pathological mechanism and design effective therapies. The Hippo pathway regulates diverse cellular processes under physiological conditions; however, its dysregulation is associated with several types of cancer, including lung, pancreatic, colorectal, breast, and prostate cancer. Consequently, compounds targeting deregulated Hippo components represent potential treatments for a broad spectrum of cancers. Nonetheless, currently, there is limited information integrating the growing evidence of this potential. Therefore, the review's objective is to provide insight into the potential efficacy of targeting the Hippo/yes-associated protein (YAP) pathway for cancer therapy. First, we describe the molecular mechanisms of the Hippo signaling pathway in physiological conditions and several cancer types. We then provide an overview of natural products and synthetic compounds targeting this pathway, highlighting their potential applications in treating diverse cancers. We also discuss relevant preclinical and clinical studies of compounds targeting the Hippo pathway in cancer. Finally, we summarize our findings and offer recommendations for future research. This review emphasizes the role of the Hippo/YAP pathway in cancer and the potential of natural products and synthetic compounds targeting this pathway for cancer treatment.

Keywords

cancer / Hippo/Yap pathway / natural products / regulation / targets

References

[1] J. D. León and A. Pareja, “Inmunología del Cáncer II: Bases Moleculares y Celulares de la Carcinogénesis,” Horizonte Médico (Lima) 19, no. 2 (2019): 84-92.

[2] B. Zhao, L. Li, Q. Lei, and K.-L. Guan, “The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis: An Updated Version,” Genes & Development 24, no. 9 (2010): 862-874.

[3] M. Harachi, K. Masui, Y. Okamura, R. Tsukui, P. S. Mischel, and N. Shibata, “mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression,” International Journal of Molecular Sciences 19, no. 10 (2018): 3267.

[4] I. Kajanova, M. Zatovicova, L. Jelenska, et al., “Impairment of Carbonic Anhydrase IX Ectodomain Cleavage Reinforces Tumorigenic and Metastatic Phenotype of Cancer Cells,” British Journal of Cancer 122, no. 11 (2020): 1590-1603.

[5] F. Sanchez-Vega, M. Mina, J. Armenia, et al., “Oncogenic Signaling Pathways in the Cancer Genome Atlas,” Cell 173, no. 2 (2018): 321-337.e10.

[6] B. Zhao, Q.-Y. Lei, and K.-L. Guan, “The Hippo-YAP Pathway: New Connections Between Regulation of Organ Size and Cancer,” Current Opinion in Cell Biology 20, no. 6 (2008): 638-646.

[7] F.-X. Yu, B. Zhao, and K.-L. Guan, “Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer,” Cell 163, no. 4 (2015): 811-828.

[8] R. Zeng and J. Dong, “The Hippo Signaling Pathway in Drug Resistance in Cancer,” Cancers 13, no. 2 (2021): 318.

[9] Y. Xiao and J. Dong, “The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective,” Cancers 13, no. 24 (2021): 6214.

[10] A. Sebio and H.-J. Lenz, “Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor,” Clinical Cancer Research 21, no. 22 (2015): 5002-5007.

[11] F.-X. Yu and K.-L. Guan, “The Hippo Pathway: Regulators and Regulations,” Genes & Development 27, no. 4 (2013): 355-371.

[12] C. L. Poon, J. I. Lin, X. Zhang, and K. F. Harvey, “The Sterile 20-Like Kinase Tao-1 Controls Tissue Growth by Regulating the Salvador-Warts-Hippo Pathway,” Developmental Cell 21, no. 5 (2011): 896-906.

[13] F. Zanconato, M. Cordenonsi, and S. Piccolo, “YAP/TAZ at the Roots of Cancer,” Cancer Cell 29, no. 6 (2016): 783-803.

[14] S. Ma, Z. Meng, R. Chen, and K.-L. Guan, “The Hippo Pathway: Biology and Pathophysiology,” Annual Review of Biochemistry 88 (2019): 577-604.

[15] R. Johnson and G. Halder, “The Two Faces of Hippo: Targeting the Hippo Pathway for Regenerative Medicine and Cancer Treatment,” Nature Reviews Drug Discovery 13, no. 1 (2014): 63-79.

[16] A. Dey, X. Varelas, and K.-L. Guan, “Targeting the Hippo Pathway in Cancer, Fibrosis, Wound Healing and Regenerative Medicine,” Nature Reviews Drug Discovery 19, no. 7 (2020): 480-494.

[17] K. Brodowska, A. Al-Moujahed, A. Marmalidou, et al., “The Clinically Used Photosensitizer Verteporfin (VP) Inhibits YAP-TEAD and Human Retinoblastoma Cell Growth In Vitro Without Light Activation,” Experimental Eye Research 124 (2014): 67-73.

[18] W. Lu, J. Wang, Y. Li, et al., “Discovery and Biological Evaluation of Vinylsulfonamide Derivatives as Highly Potent, Covalent TEAD Autopalmitoylation Inhibitors,” European Journal of Medicinal Chemistry 184 (2019): 111767.

[19] J. Zhang, J.-Y. Ji, M. Yu, et al., “YAP-Dependent Induction of Amphiregulin Identifies a Non-Cell-Autonomous Component of the Hippo Pathway,” Nature Cell Biology 11, no. 12 (2009): 1444-1450.

[20] D. Wennmann, B. Vollenbröker, A. Eckart, et al., “The Hippo Pathway Is Controlled by Angiotensin II Signaling and Its Reactivation Induces Apoptosis in Podocytes,” Cell Death & Disease 5, no. 11 (2014): e1519.

[21] F.-X. Yu, B. Zhao, N. Panupinthu, et al., “Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling,” Cell 150, no. 4 (2012): 780-791.

[22] M. Moloudizargari, M. H. Asghari, S. F. Nabavi, et al., “Targeting Hippo Signaling Pathway by Phytochemicals in Cancer Therapy,” in Seminars in Cancer Biology (Elsevier, 2022).

[23] C. Lorthongpanich, T. Charoenwongpaiboon, P. Supakun, M. Klaewkla, P. Kheolamai, and S. Issaragrisil, “Fisetin Inhibits Osteogenic Differentiation of Mesenchymal Stem Cells via the Inhibition of YAP,” Antioxidants 10, no. 6 (2021): 879.

[24] E. H. Lee, K.-I. Park, K.-Y. Kim, et al., “Liquiritigenin Inhibits Hepatic Fibrogenesis and TGF-β1/Smad With Hippo/YAP Signal,” Phytomedicine 62 (2019): 152780.

[25] J. Li, H. Wang, L. Wang, et al., “Decursin Inhibits the Growth of HepG2 Hepatocellular Carcinoma Cells via Hippo/YAP Signaling Pathway,” Phytotherapy Research 32, no. 12 (2018): 2456-2465.

[26] A. P. Gupta, P. Pandotra, M. Kushwaha, S. Khan, R. Sharma, and S. Gupta, “Alkaloids: A Source of Anticancer Agents From Nature,” Studies in Natural Products Chemistry 46 (2015): 341-445.

[27] Y. Zhang, M. Wang, X. Xu, Y. Liu, and C. Xiao, “Matrine Promotes Apoptosis in SW480 Colorectal Cancer Cells via Elevating MIEF1-Related Mitochondrial Division in a Manner Dependent on LATS2-Hippo Pathway,” Journal of Cellular Physiology 234, no. 12 (2019): 22731-22741.

[28] R. Kawamoto, N. Nakano, H. Ishikawa, et al., “Narciclasine Is a Novel YAP Inhibitor That Disturbs Interaction Between YAP and TEAD4,” BBA Advances 1 (2021): 100008.

[29] F. Yan, M. Qian, H. Luo, et al., “A Novel Natural Compound Shikonin Inhibits YAP Function by Activating AMPK,” TMR Modern Herbal Medicine 1 (2018): 136-142.

[30] C. Ye, W. Wang, G. Xia, et al., “A Novel Curcumin Derivative cl-6 Exerts Antitumor Effect in Human Gastric Cancer Cells by Inducing Apoptosis Through Hippo-YaP Signaling Pathway,” OncoTargets and Therapy 12 (2019): 2259-2269.

[31] K. F. Harvey, X. Zhang, and D. M. Thomas, “The Hippo Pathway and Human Cancer,” Nature Reviews Cancer 13, no. 4 (2013): 246-257.

[32] S. Moon, S. Yeon Park, and H. Woo Park, “Regulation of the Hippo Pathway in Cancer Biology,” Cellular and Molecular Life Sciences 75 (2018): 2303-2319.

[33] P. C. Calses, J. J. Crawford, J. R. Lill, and A. Dey, “Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities,” Trends in Cancer 5, no. 5 (2019): 297-307.

[34] R. W. Justice, O. Zilian, D. F. Woods, M. Noll, and P. J. Bryant, “The Drosophila Tumor Suppressor Gene Warts Encodes a Homolog of Human Myotonic Dystrophy Kinase and Is Required for the Control of Cell Shape and Proliferation,” Genes & Development 9, no. 5 (1995): 534-546.

[35] N. Tapon, K. F. Harvey, D. W. Bell, et al., “salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines,” Cell 110, no. 4 (2002): 467-478.

[36] K. F. Harvey, C. M. Pfleger, and I. K. Hariharan, “The Drosophila Mst Ortholog, Hippo, Restricts Growth and Cell Proliferation and Promotes Apoptosis,” Cell 114, no. 4 (2003): 457-467.

[37] Z.-C. Lai, X. Wei, T. Shimizu, et al., “Control of Cell Proliferation and Apoptosis by Mob as Tumor Suppressor, Mats,” Cell 120, no. 5 (2005): 675-685.

[38] J. Huang, S. Wu, J. Barrera, K. Matthews, and D. Pan, “The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP,” Cell 122, no. 3 (2005): 421-434.

[39] H. Oh and K. D. Irvine, “In Vivo Regulation of Yorkie Phosphorylation and Localization,” Development 135, no. 6 (2008): 1081-1088.

[40] R. Nolo, C. M. Morrison, C. Tao, X. Zhang, and G. Halder, “The Bantam microRNA Is a Target of the Hippo Tumor-Suppressor Pathway,” Current Biology 16, no. 19 (2006): 1895-1904.

[41] C. Zhu, L. Li, and B. Zhao, “The Regulation and Function of YAP Transcription Co-Activator,” Acta Biochimica et Biophysica Sinica 47, no. 1 (2015): 16-28.

[42] B. Zhao, X. Wei, W. Li, et al., “Inactivation of YAP Oncoprotein by the Hippo Pathway Is Involved in Cell Contact Inhibition and Tissue Growth Control,” Genes & Development 21, no. 21 (2007): 2747-2761.

[43] M. Overholtzer, J. Zhang, G. A. Smolen, et al., “Transforming Properties of YAP, a Candidate Oncogene on the Chromosome 11q22 Amplicon,” Proceedings of the National Academy of Sciences of the United States of America 103, no. 33 (2006): 12405-12410.

[44] T. Mizuno, H. Murakami, M. Fujii, et al., “YAP Induces Malignant Mesothelioma Cell Proliferation by Upregulating Transcription of Cell Cycle-Promoting Genes,” Oncogene 31, no. 49 (2012): 5117-5122.

[45] R. Fan, N.-G. Kim, and B. M. Gumbiner, “Regulation of Hippo Pathway by Mitogenic Growth Factors via Phosphoinositide 3-Kinase and Phosphoinositide-Dependent Kinase-1,” Proceedings of the National Academy of Sciences of the United States of America 110, no. 7 (2013): 2569-2574.

[46] S. Dupont, L. Morsut, M. Aragona, et al., “Role of YAP/TAZ in Mechanotransduction,” Nature 474, no. 7350 (2011): 179-183.

[47] K. Wada, K. Itoga, T. Okano, S. Yonemura, and H. Sasaki, “Hippo Pathway Regulation by Cell Morphology and Stress Fibers,” Development (Cambridge, England) 138, no. 18 (2011): 3907-3914.

[48] M. Aragona, T. Panciera, A. Manfrin, et al., “A Mechanical Checkpoint Controls Multicellular Growth Through YAP/TAZ Regulation by Actin-Processing Factors,” Cell 154, no. 5 (2013): 1047-1059.

[49] G. C. Fletcher, A. Elbediwy, I. Khanal, P. S. Ribeiro, N. Tapon, and B. J. Thompson, “The Spectrin Cytoskeleton Regulates the Hippo Signalling Pathway,” EMBO Journal 34, no. 7 (2015): 940-954.

[50] M. M. Pathak, J. L. Nourse, T. Tran, et al., “Stretch-Activated Ion Channel Piezo1 Directs Lineage Choice in Human Neural Stem Cells,” PNAS 111, no. 45 (2014): 16148-16153.

[51] F. Yin, J. Yu, Y. Zheng, Q. Chen, N. Zhang, and D. Pan, “Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2,” Cell 154, no. 6 (2013): 1342-1355.

[52] W. Li, L. You, J. Cooper, et al., “Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus,” Cell 140, no. 4 (2010): 477-490.

[53] S. Basu, N. F. Totty, M. S. Irwin, M. Sudol, and J. Downward, “Akt Phosphorylates the Yes-Associated Protein, YAP, to Induce Interaction With 14-3-3 and Attenuation of p73-Mediated Apoptosis,” Molecular Cell 11, no. 1 (2003): 11-23.

[54] Y. T. Yeung, A. Guerrero-Castilla, M. Cano, M. F. Muñoz, A. Ayala, and S. Argüelles, “Dysregulation of the Hippo Pathway Signaling in Aging and Cancer,” Pharmacological Research 143 (2019): 151-165.

[55] Y. Wang, X. Xu, D. Maglic, et al., “Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer,” Cell Reports 25, no. 5 (2018): 1304-1317.e5.

[56] P. Kullar, D. Pearson, D. Malley, V. Collins, and K. Ichimura, “CpG Island Hypermethylation of the Neurofibromatosis Type 2 (NF2) Gene Is Rare in Sporadic Vestibular Schwannomas,” Neuropathology and Applied Neurobiology 36, no. 6 (2010): 505-514.

[57] H. J. Oh, K.-K. Lee, S. J. Song, et al., “Role of the Tumor Suppressor RASSF1A in Mst1-Mediated Apoptosis,” Cancer Research 66, no. 5 (2006): 2562-2569.

[58] Z.-G. Pan, V. I. Kashuba, X.-Q. Liu, et al., “High Frequency Somatic Mutations in RASSF1A in Nasopharyngeal Carcinoma,” Cancer Biology & Therapy 4, no. 10 (2005): 1116-1122.

[59] M. S. Kim, J. Louwagie, B. Carvalho, et al., “Promoter DNA Methylation of Oncostatin M Receptor-β as a Novel Diagnostic and Therapeutic Marker in Colon Cancer,” PLoS ONE 4, no. 8 (2009): e6555.

[60] H. Murakami, T. Mizuno, T. Taniguchi, et al., “LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma,” Cancer Research 71, no. 3 (2011): 873-883.

[61] K.-P. Lee, J.-H. Lee, T.-S. Kim, et al., “The Hippo-Salvador Pathway Restrains Hepatic Oval Cell Proliferation, Liver Size, and Liver Tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 18 (2010): 8248-8253.

[62] L. Lu, Y. Li, S. M. Kim, et al., “Hippo Signaling Is a Potent In Vivo Growth and Tumor Suppressor Pathway in the Mammalian Liver,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 4 (2010): 1437-1442.

[63] A. Kapoor, W. Yao, H. Ying, et al., “Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer,” Cell 158, no. 1 (2014): 185-197.

[64] N. Yang, C. D. Morrison, P. Liu, et al., “TAZ Induces Growth Factor-Independent Proliferation Through Activation of EGFR Ligand Amphiregulin,” Cell Cycle 11, no. 15 (2012): 2922-2930.

[65] B. Zhao, L. Li, K. Tumaneng, C.-Y. Wang, and K.-L. Guan, “A Coordinated Phosphorylation by Lats and CK1 Regulates YAP Stability Through SCFβ-TRCP,” Genes & Development 24, no. 1 (2010): 72-85.

[66] H. J. Janse van Rensburg and X. Yang, “The Roles of the Hippo Pathway in Cancer Metastasis,” Cellular Signalling 28, no. 11 (2016): 1761-1772.

[67] Q. Zuo, R. Zhang, B. Li, et al., “MicroRNA-141 Inhibits Tumor Growth and Metastasis in Gastric Cancer by Directly Targeting Transcriptional Co-Activator With PDZ-Binding Motif, TAZ,” Cell Death & Disease 6, no. 1 (2015): e1623.

[68] C. S. Anderson, T. Robinson, R. I. Lindley, et al., “Low-Dose Versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke,” New England Journal of Medicine 374, no. 24 (2016): 2313-2323.

[69] D. E. Mason, J. M. Collins, J. H. Dawahare, et al., “YAP and TAZ Limit Cytoskeletal and Focal Adhesion Maturation to Enable Persistent Cell Motility,” Journal of Cell Biology 218, no. 4 (2019): 1369-1389.

[70] Y. Hsu, J. Hung, S. Chou, et al., “Angiomotin Decreases Lung Cancer Progression by Sequestering Oncogenic YAP/TAZ and Decreasing Cyr61 Expression,” Oncogene 34, no. 31 (2015): 4056-4068.

[71] K. Liang, G. Zhou, Q. Zhang, J. Li, and C. Zhang, “Expression of Hippo Pathway in Colorectal Cancer,” Saudi Journal of Gastroenterology 20, no. 3 (2014): 188-194.

[72] J. M. Lamar, P. Stern, H. Liu, J. W. Schindler, Z.-G. Jiang, and R. O. Hynes, “The Hippo Pathway Target, YAP, Promotes Metastasis Through Its TEAD-Interaction Domain,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 37 (2012): E2441-E2450.

[73] J. Wang, C. Rouse, J. S. Jasper, and A. M. Pendergast, “ABL Kinases Promote Breast Cancer Osteolytic Metastasis by Modulating Tumor-Bone Interactions Through TAZ and STAT5 Signaling,” Science Signaling 9, no. 413 (2016): ra12.

[74] P. C. Hsu, C. T. Yang, D. M. Jablons, and L. You, “The Crosstalk Between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC),” Cancers (Basel) 12, no. 6 (2020): 1361.

[75] Y. Si, X. Ji, X. Cao, et al., “Src Inhibits the Hippo Tumor Suppressor Pathway Through Tyrosine Phosphorylation of Lats1,” Cancer Research 77, no. 18 (2017): 4868-4880.

[76] D. H. Kim, H. I. Choi, J. S. Park, et al., “Src-Mediated Crosstalk Between FXR and YAP Protects Against Renal Fibrosis,” FASEB Journal 33, no. 10 (2019): 11109-11122.

[77] K. Grannas, L. Arngården, P. Lönn, et al., “Crosstalk Between Hippo and TGFβ: Subcellular Localization of YAP/TAZ/Smad Complexes,” Journal of Molecular Biology 427, no. 21 (2015): 3407-3415.

[78] C. Li, S. Wang, Z. Xing, et al., “A ROR1-HER3-lncRNA Signalling Axis Modulates the Hippo-YAP Pathway to Regulate Bone Metastasis,” Nature Cell Biology 19, no. 2 (2017): 106-119.

[79] Y. Jiang, L. Fu, B. Liu, and F. Li, “YAP Induces FAK Phosphorylation to Inhibit Gastric Cancer Cell Proliferation via Upregulation of HMGB1,” International Journal of Biological Macromolecules 262, no. P1 (2024): 130037.

[80] J. Shen, B. Cao, Y. Wang, et al., “Hippo Component YAP Promotes Focal Adhesion and Tumour Aggressiveness via Transcriptionally Activating THBS1/FAK Signalling in Breast Cancer,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 175.

[81] A. Pocaterra, P. Romani, and S. Dupont, “YAP/TAZ Functions and Their Regulation at a Glance,” Journal of Cell Science 133, no. 2 (2020): jcs230425.

[82] K. Zhang, H. X. Qi, Z. M. Hu, et al., “YAP and TAZ Take Center Stage in Cancer,” Biochemistry 54, no. 43 (2015): 6555-6566.

[83] R. B. Mokhtari, N. Ashayeri, L. Baghaie, et al., “The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment,” Cancers (Basel) 15, no. 13 (2023): 3468.

[84] Z. Wang, F. Wang, X.-Y. Ding, et al., “Hippo/YAP Signaling Choreographs the Tumor Immune Microenvironment to Promote Triple Negative Breast Cancer Progression via TAZ/IL-34 Axis,” Cancer Letters 527 (2022): 174-190.

[85] X. Chen, W. Yuan, Y. Li, J. Luo, and N. Hou, “Role of Hippo-YAP1/TAZ Pathway and Its Crosstalk in Cardiac Biology,” International Journal of Biological Sciences 16, no. 13 (2020): 2454-2463.

[86] S. M. White, S. Murakami, and C. Yi, “The Complex Entanglement of Hippo-Yap/Taz Signaling in Tumor Immunity,” Oncogene 38, no. 16 (2019): 2899-2909.

[87] D. E. Pefani, D. Pankova, A. G. Abraham, et al., “TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation,” Molecular Cell 63, no. 1 (2016): 156-166.

[88] M. Ghomlaghi, M. Theocharous, S.-Y. Shin, E. O. Neill, and L. K. Nguyen, “Systems Modelling of TGF-β/Hippo Signalling Crosstalk Uncovers Molecular Switches That Coordinate YAP Transcriptional Complexes (submitted to iScience),” preprint, bioRxiv, 2022.

[89] S. Ben Mimoun and A. Mauviel, “Molecular Mechanisms Underlying TGF-ß/Hippo Signaling Crosstalks—Role of Baso-Apical Epithelial Cell Polarity,” International Journal of Biochemistry & Cell Biology 98 (2018): 75-81.

[90] W. Zhang, N. Nandakumar, Y. Shi, et al., “Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma,” Science Signaling 7, no. 324 (2014): ra42.

[91] Z. Zhang, J. Du, S. Wang, et al., “OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ,” Molecular Cell 73, no. 1 (2019): 7-21.

[92] W. Yang, M. Zhang, T. X. Zhang, et al., “YAP/TAZ Mediates Resistance to KRAS Inhibitors Through Inhibiting Proapoptosis and Activating the SLC7A5/mTOR Axis,” JCI Insight 9, no. 24 (2024): e178535.

[93] E. Rozengurt and G. Eibl, “Crosstalk Between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance,” Cancers (Basel) 13, no. 20 (2021): 5126.

[94] C. Wang, C. Gu, K. J. Jeong, et al., “YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway,” Cancer Research 77, no. 7 (2017): 1637-1648.

[95] S.-H. Jeong and D.-S. Lim, “Abstract IA09: The Crosstalk Between Hippo-YAP/TAZ and PTEN-AKT Signaling in Liver Metabolic Dysregulation and Tumorigenesis,” Molecular Cancer Research 18, no. S8 (2020): IA09.

[96] J. P. Rodrigo, T. Rodríguez-Santamarta, D. Corte, et al., “Hippo-YAP Signaling Activation and Cross-Talk With PI3K in Oral Cancer: A Retrospective Cohort Study,” Oral Diseases 30, no. 2 (2024): 149-162.

[97] X. Qian, L. He, M. Hao, et al., “YAP Mediates the Interaction Between the Hippo and PI3K/Akt Pathways in Mesangial Cell Proliferation in Diabetic Nephropathy,” Acta Diabetologica 58, no. 1 (2021): 47-62.

[98] H. Xia, X. Dai, H. Yu, et al., “EGFR-PI3K-PDK1 Pathway Regulates YAP Signaling in Hepatocellular Carcinoma: The Mechanism and Its Implications in Targeted Therapy,” Cell Death & Disease 9, no. 3 (2018): 269.

[99] X. J. Li, S. H. Leem, M. H. Park, and S. M. Kim, “Regulation of YAP Through an Akt-Dependent Process by 3, 3'-Diindolylmethane in Human Colon Cancer Cells,” International Journal of Oncology 43, no. 6 (2013): 1992-1998.

[100] Y. Ding, G. Wang, M. Zhan, et al., “Hippo Signaling Suppresses Tumor Cell Metastasis via a Yki-Src42A Positive Feedback Loop,” Cell Death & Disease 12, no. 12 (2021): 1126.

[101] B. Labibi, M. Bashkurov, J. L. Wrana, and L. Attisano, “Modeling the Control of TGF-β/Smad Nuclear Accumulation by the Hippo Pathway Effectors, Taz/Yap,” iScience 23, no. 8 (2020): 101416.

[102] C. Zhang, W. Wei, S. Tu, et al., “Upregulation of CYR61 by TGF-β and YAP Signaling Exerts a Counter-Suppression of Hepatocellular Carcinoma,” Journal of Biological Chemistry 300, no. 4 (2024): 107208.

[103] M. R. Zinatizadeh, S. R. Miri, P. K. Zarandi, et al., “The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in Cancer Metastasis,” Genes & Diseases 8, no. 1 (2021): 48-60.

[104] T. J. Hagenbeek, J. R. Zbieg, M. Hafner, et al., “An Allosteric Pan-TEAD Inhibitor Blocks Oncogenic YAP/TAZ Signaling and Overcomes KRAS G12C Inhibitor Resistance,” Nat Cancer 4, no. 6 (2023): 812-828.

[105] L. Jiang, J. Li, C. Zhang, Y. Shang, and J. Lin, “YAP‑Mediated Crosstalk Between the Wnt and Hippo Signaling Pathways (Review),” Molecular Medicine Reports 22, no. 5 (2020): 4101-4106.

[106] M. Astone, C. Tesoriero, M. Schiavone, et al., “Wnt/β-Catenin Signaling Regulates Yap/Taz Activity During Embryonic Development in Zebrafish,” International Journal of Molecular Sciences 25, no. 18 (2024): 10005.

[107] V. Kriz and V. Korinek, “Wnt, RSPO and Hippo Signalling in the Intestine and Intestinal Stem Cells,” Genes (Basel) 9, no. 1 (2018): 20.

[108] M. Imajo, K. Miyatake, A. Iimura, A. Miyamoto, and E. Nishida, “A Molecular Mechanism That Links Hippo Signalling to the Inhibition of Wnt/β-Catenin Signalling,” EMBO Journal 31, no. 5 (2012): 1109-1122.

[109] N. Li, N. Lu, and C. Xie, “The Hippo and Wnt Signalling Pathways: Crosstalk During Neoplastic Progression in Gastrointestinal Tissue,” FEBS Journal 286, no. 19 (2019): 3745-3756.

[110] H. Gilgenkrantz, “[The World According to YAP: A Continuous Cross-Talk Between Wnt and Hippo Pathways],” Medecine Sciences 29, no. 10 (2013): 868-874.

[111] F. Xu, J. Zhang, and D. Ma, “[Crosstalk of Hippo/YAP and Wnt/β-Catenin Pathways],” Yi Chuan 36, no. 2 (2014): 95-102.

[112] W. M. Konsavage and G. S. Yochum, “Intersection of Hippo/YAP and Wnt/β-Catenin Signaling Pathways,” Acta Biochimica et Biophysica Sinica (Shanghai) 45, no. 2 (2013): 71-79.

[113] W. I. Seo, S. Park, J. Gwak, et al., “Wnt Signaling Promotes Androgen-Independent Prostate Cancer Cell Proliferation Through Up-Regulation of the Hippo Pathway Effector YAP,” Biochemical and Biophysical Research Communications 486, no. 4 (2017): 1034-1039.

[114] P. Sileo, C. Simonin, P. Melnyk, M. C. Chartier-Harlin, and P. Cotelle, “Crosstalk Between the Hippo Pathway and the Wnt Pathway in Huntington's Disease and Other Neurodegenerative Disorders,” Cells 11, no. 22 (2022): 3631.

[115] Z. Lin, P. Zhou, A. von Gise, et al., “Pi3kcb Links Hippo-YAP and PI3K-AKT Signaling Pathways to Promote Cardiomyocyte Proliferation and Survival,” Circulation Research 116, no. 1 (2015): 35-45.

[116] N. Borreguero-Muñoz, G. C. Fletcher, M. Aguilar-Aragon, A. Elbediwy, Z. I. Vincent-Mistiaen, and B. J. Thompson, “The Hippo Pathway Integrates PI3K-Akt Signals With Mechanical and Polarity Cues to Control Tissue Growth,” PLoS Biology 17, no. 10 (2019): e3000509.

[117] W. Zhuo and Y. Kang, “Lnc-ing ROR1-HER3 and Hippo Signalling in Metastasis,” Nature Cell Biology 19, no. 2 (2017): 81-83.

[118] C. G. Hansen, T. Moroishi, and K. L. Guan, “YAP and TAZ: A Nexus for Hippo Signaling and Beyond,” Trends in Cell Biology 25, no. 9 (2015): 499-513.

[119] M. Santucci, T. Vignudelli, S. Ferrari, et al., “The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment,” Journal of Medicinal Chemistry 58, no. 12 (2015): 4857-4873.

[120] Y. Liu-Chittenden, B. Huang, J. S. Shim, et al., “Genetic and Pharmacological Disruption of the TEAD-YAP Complex Suppresses the Oncogenic Activity of YAP,” Genes & Development 26, no. 12 (2012): 1300-1305.

[121] G. Sorrentino, N. Ruggeri, V. Specchia, et al., “Metabolic Control of YAP and TAZ by the Mevalonate Pathway,” Nature Cell Biology 16, no. 4 (2014): 357-366.

[122] E. Rozengurt and G. Eibl, “Crosstalk Between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance,” Cancers 13, no. 20 (2021): 5126.

[123] T. Moroishi, C. G. Hansen, and K.-L. Guan, “The Emerging Roles of YAP and TAZ in Cancer,” Nature Reviews Cancer 15, no. 2 (2015): 73-79.

[124] V. Liju, A. Muraleedharan, D. Jayaram, et al., YAP Activation and Hippo Signaling Suppression by PKC Eta Promote Triple-Negative Breast Cancer Metastasis (Research Square, 2023).

[125] T. Moroishi, H. W. Park, B. Qin, et al., “A YAP/TAZ-Induced Feedback Mechanism Regulates Hippo Pathway Homeostasis,” Genes & Development 29, no. 12 (2015): 1271-1284.

[126] Z. Jiang, X. Chen, K. Chen, et al., “YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine,” Nutrients 8, no. 10 (2016): 546.

[127] Y. N. Kim, S. R. Choe, K. H. Cho, et al., “Resveratrol Suppresses Breast Cancer Cell Invasion by Inactivating a RhoA/YAP Signaling Axis,” Experimental & Molecular Medicine 49, no. 2 (2017): e296.

[128] G. Xu, J. Chen, G. Wang, et al., “Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway,” Molecular Therapy-Oncolytics 16 (2020): 124-133.

[129] E. H. Lee, S. Y. Baek, J. Y. Park, and Y. W. Kim, “Emodin in Rheum undulatum Inhibits Oxidative Stress in the Liver via AMPK With Hippo/Yap Signalling Pathway,” Pharmaceutical Biology 58, no. 1 (2020): 333-341.

[130] H. Zhao, M. Liu, H. Liu, R. Suo, and C. Lu, “Naringin Protects Endothelial Cells From Apoptosis and Inflammation by Regulating the Hippo-YAP Pathway,” Bioscience Reports 40, no. 3 (2020): BSR20193431.

[131] D. Lei, L. Chengcheng, Q. Xuan, et al., “Quercetin Inhibited Mesangial Cell Proliferation of Early Diabetic Nephropathy Through the Hippo Pathway,” Pharmacological Research 146 (2019): 104320.

[132] D. Cao, G.-Y. Zhu, Y. Lu, et al., “Luteolin Suppresses Epithelial-Mesenchymal Transition and Migration of Triple-Negative Breast Cancer Cells by Inhibiting YAP/TAZ Activity,” Biomedicine & Pharmacotherapy 129 (2020): 110462.

[133] A. R. Kim, K. M. Kim, M. R. Byun, et al., “(-)-Epigallocatechin-3-Gallate Stimulates Myogenic Differentiation Through TAZ Activation,” Biochemical and Biophysical Research Communications 486, no. 2 (2017): 378-384.

[134] A. Li, K. Gu, Q. Wang, et al., “Epigallocatechin-3-Gallate Affects the Proliferation, Apoptosis, Migration and Invasion of Tongue Squamous Cell Carcinoma Through the Hippo-TAZ Signaling Pathway,” International Journal of Molecular Medicine 42, no. 5 (2018): 2615-2627.

[135] L. Zhu, S. Huang, J. Li, et al., “Sophoridine Inhibits Lung Cancer Cell Growth and Enhances Cisplatin Sensitivity Through Activation of the p53 and Hippo Signaling Pathways,” Gene 742 (2020): 144556.

[136] T. W. Kim, “Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer,” International Journal of Molecular Sciences 24, no. 10 (2023): 9076.

[137] K. Nakatani, T. Maehama, M. Nishio, et al., “Alantolactone Is a Natural Product That Potently Inhibits YAP1/TAZ Through Promotion of Reactive Oxygen Species Accumulation,” Cancer Science 112, no. 10 (2021): 4303-4316.

[138] S.-H. Kim, H. Jin, R. Y. Meng, et al., “Activating Hippo Pathway via Rassf1 by Ursolic Acid Suppresses the Tumorigenesis of Gastric Cancer,” International Journal of Molecular Sciences 20, no. 19 (2019): 4709.

[139] Y. Zhang, C. Xin, J. Qiu, and Z. Wang, “Essential Oil From Pinus koraiensis Pinecones Inhibits Gastric Cancer Cells via the HIPPO/YAP Signaling Pathway,” Molecules (Basel, Switzerland) 24, no. 21 (2019): 3851.

[140] F. Vandresen, H. Falzirolli, S. A. A. Batista, et al., “Novel R-(+)-Limonene-Based Thiosemicarbazones and Their Antitumor Activity Against Human Tumor Cell Lines,” European Journal of Medicinal Chemistry 79 (2014): 110-116.

[141] K. Li, K. Hao, Y. Zhang, et al., “C21 Fraction Refined From Marsdenia tenacissima-Induced Apoptosis Is Enhanced by Suppression of Autophagy in Human Gastric Cell Lines,” ACS Omega 5, no. 39 (2020): 25156-25163.

[142] Y. Gao, Q. Shi, S. Xu, et al., “Curcumin Promotes KLF5 Proteasome Degradation Through Downregulating YAP/TAZ in Bladder Cancer Cells,” International Journal of Molecular Sciences 15, no. 9 (2014): 15173-15187.

[143] A. R. Nam, J. Yoon, K.-S. Oh, et al., “Abstract 5334: Targeting the Hippo Transducer YAP Overcomes Trastuzumab-Resistance in HER2-Positive Cancers,” Cancer Research 82, no. S12 (2022): 5334.

[144] A. R. Nam, J. Yoon, K.-S. Oh, et al., “Abstract 3872: Targeting of YAP Overcomes Trastuzumab-Resistance and Promotes Immune Responses in HER2-Positive Cancers,” Cancer Research 83, no. S7 (2023): 3872.

[145] C. L. E. Wong, M. Y. K. Kiang, and K. K. G. Leung, “Abstract 7207: Targeting Hippo Signaling Pathway to Overcome Chemoresistance in Glioblastoma,” Cancer Research 84, no. S6 (2024): 7207.

[146] S. Park, W. J. Ryu, T. Y. Kim, et al., “Overcoming BRAF and CDK4/6 Inhibitor Resistance by Inhibiting MAP3K3-Dependent Protection Against YAP Lysosomal Degradation,” Experimental & Molecular Medicine 56, no. 4 (2024): 987-1000.

[147] R. Malla, D. B. Kundrapu, P. Bhamidipati, G. P. Nagaraju, and N. Muniraj, “Unleashing the Power of Yes-Associated Protein in Ferroptosis and Drug Resistance in Breast Cancer, With a Special Focus on Therapeutic Strategies,” Cancers (Basel) 15, no. 24 (2023): 5728.

[148] L. Lin, A. J. Sabnis, E. Chan, et al., “The Hippo Effector YAP Promotes Resistance to RAF- and MEK-Targeted Cancer Therapies,” Nature Genetics 47, no. 3 (2015): 250-256.

[149] T. S. Gujral and M. W. Kirschner, “Hippo Pathway Mediates Resistance to Cytotoxic Drugs,” Proceedings of the National Academy of Sciences of the United States of America 114, no. 18 (2017): E3729-E3738.

[150] M. H. Kim and J. Kim, “Role of YAP/TAZ Transcriptional Regulators in Resistance to Anti-Cancer Therapies,” Cellular and Molecular Life Sciences 74, no. 8 (2017): 1457-1474.

[151] N. Chatterjee, V. Olivas, W. Wu, B. Powell, and T. Bivona, “Abstract 3878: Targeting Hippo-YAP, BRD4 and RAS-MAPK Interplay in Lung Cancer to Forestall Drug Resistance,” Cancer Research 83, no. S7 (2023): 3878.

[152] R. Zeng and J. Dong, “The Hippo Signaling Pathway in Drug Resistance in Cancer,” Cancers (Basel) 13, no. 2 (2021): 318.

[153] R. Kumar and W. Hong, “Hippo Signaling at the Hallmarks of Cancer and Drug Resistance,” Cells 13, no. 7 (2024): 564.

[154] W. Mao, J. Mai, H. Peng, J. Wan, and T. Sun, “YAP in Pancreatic Cancer: Oncogenic Role and Therapeutic Strategy,” Theranostics 11, no. 4 (2021): 1753-1762.

[155] J. M. Franklin, Z. Wu, and K. L. Guan, “Insights Into Recent Findings and Clinical Application of YAP and TAZ in Cancer,” Nature Reviews Cancer 23, no. 8 (2023): 512-525.

[156] J. H. Park and H. W. Park, “Abstract B13: Cancer Metabolism Sensitizes Metformin Treatment by Targeting the Hippo-YAP/TAZ Pathway,” Molecular Cancer Research 18, no. S8 (2020): B13.

[157] Z. Wang, C. Yang, H. Zhang, et al., “Transformable Supramolecular Nanomedicine Targeted Activating Hippo Pathway for Triple-Negative Breast Cancer Growth and Metastasis Inhibition,” ACS Nano 16, no. 9 (2022): 14644-14657.

[158] H. Yokoyama, “Chromatin-Binding Proteins Moonlight as Mitotic Microtubule Regulators,” Trends in Cell Biology 26, no. 3 (2016): 161-164.

[159] A. Kumar, B. BharathwajChetty, M. K. Manickasamy, et al., “Natural Compounds Targeting YAP/TAZ Axis in Cancer: Current State of Art and Challenges,” Pharmacological Research 203 (2024): 107167.

[160] D. Zhou, C. Conrad, F. Xia, et al., “Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development Through Inactivation of the Yap1 Oncogene,” Cancer Cell 16, no. 5 (2009): 425-438.

[161] D. Pan, “The Hippo Signaling Pathway in Development and Cancer,” Developmental Cell 19, no. 4 (2010): 491-505.

[162] Z. Meng, T. Moroishi, and K.-L. Guan, “Mechanisms of Hippo Pathway Regulation,” Genes & Development 30, no. 1 (2016): 1-17.

[163] L. Hou, L. Chen, and L. Fang, “Scutellarin Inhibits Proliferation, Invasion, and Tumorigenicity in Human Breast Cancer Cells by Regulating HIPPO-YAP Signaling Pathway,” Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 23 (2017): 5130-5138.

[164] L. Zan, Q. Chen, L. Zhang, and X. Li, “Epigallocatechin Gallate (EGCG) Suppresses Growth and Tumorigenicity in Breast Cancer Cells by Downregulation of miR-25,” Bioengineered 10, no. 1 (2019): 374-382.

[165] D. Lin, X. Lin, T. He, and G. Xie, “Gambogic Acid Inhibits the Progression of Gastric Cancer via circRNA_ASAP2/miR-33a-5p/CDK7 Axis,” Cancer Management and Research 12 (2020): 9221-9233.

[166] G. Zhang, S. Dai, Y. Chen, et al., “Aqueous Extract of Taxus chinensis var. mairei Regulates the Hippo-YAP Pathway and Promotes Apoptosis of Non-Small Cell Lung Cancer via ATF3 In Vivo and In Vitro,” Biomedicine & Pharmacotherapy 138 (2021): 111506.

[167] F. Jin, X. Ni, S. Yu, et al., “The Ethyl Acetate Extract From Celastrus orbiculatus Suppresses Non-Small-Cell Lung Cancer by Activating Hippo Signaling and Inhibiting YAP Nuclear Translocation,” Phytomedicine 114 (2023): 154761.

[168] F. Sha, D. Xin, J. Xu, et al., “Curcumin Inhibits Colorectal Cancer Development by Blocking the YAP/TAZ Signaling Axis,” Biocell 48, no. 3 (2024): 443-451.

[169] H. Hong, D. Baatar, and S. G. Hwang, “Anticancer Activities of Ginsenosides, the Main Active Components of Ginseng,” Evidence-Based Complementary and Alternative Medicine 2021, no. 1 (2021): 8858006.

[170] Z. Wang, C. Yang, H. Zhang, et al., “In Situ Transformable Supramolecular Nanomedicine Targeted Activating Hippo Pathway for Triple-Negative Breast Cancer Growth and Metastasis Inhibition,” ACS Nano 16, no. 9 (2022): 14644-14657.

[171] P. G. Sasikumar, N. S. Sudarshan, S. Adurthi, et al., “PD-1 Derived CA-170 Is an Oral Immune Checkpoint Inhibitor That Exhibits Preclinical Anti-Tumor Efficacy,” Communications Biology 4, no. 1 (2021): 699.

[172] J. Xie, X. Si, S. Gu, et al., “Allosteric Inhibitors of SHP2 With Therapeutic Potential for Cancer Treatment,” Journal of Medicinal Chemistry 60, no. 24 (2017): 10205-10219.

[173] A. Jatoi, N. Ellison, P. A. Burch, et al., “A Phase II Trial of Green Tea in the Treatment of Patients With Androgen Independent Metastatic Prostate Carcinoma,” Cancer: Interdisciplinary International Journal of the American Cancer Society 97, no. 6 (2003): 1442-1446.

[174] B. Zagiel, P. Melnyk, and P. Cotelle, “Progress With YAP/TAZ-TEAD Inhibitors: A Patent Review (2018-Present),” Expert Opinion on Therapeutic Patents 32, no. 8 (2022): 899-912.

[175] T. A. Yap, D. J. Kwiatkowski, J. Desai, et al., “Abstract CT006: First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor of Yes-Associated Protein (YAP)/Transcriptional Enhancer Activator Domain (TEAD), in Patients (pts) With Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors With Neurofibromatosis 2 (NF2) Mutations,” Cancer Research 83, no. S8 (2023): CT006.

[176] J. E. Lee, H. S. Park, D. Lee, et al., “Hippo Pathway Effector YAP Inhibition Restores the Sensitivity of EGFR-TKI in Lung Adenocarcinoma Having Primary or Acquired EGFR-TKI Resistance,” Biochemical and Biophysical Research Communications 474, no. 1 (2016): 154-160.

[177] W. Zhou, A. Lim, M. Edderkaoui, et al., “Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer,” International Journal of Biological Sciences 20, no. 1 (2024): 15-28.

[178] M. Luo, Y. Xu, H. Chen, et al., “Advances of Targeting the YAP/TAZ-TEAD Complex in the Hippo Pathway for the Treatment of Cancers,” European Journal of Medicinal Chemistry 244 (2022): 114847.

[179] L. Wu and X. Yang, “Targeting the Hippo Pathway for Breast Cancer Therapy,” Cancers (Basel) 10, no. 11 (2018): 422.

[180] S. Ma, T. Tang, G. Probst, et al., “Transcriptional Repression of Estrogen Receptor Alpha by YAP Reveals the Hippo Pathway as Therapeutic Target for ER⁺ Breast Cancer,” Nature Communications 13, no. 1 (2022): 1061.

[181] X. Li, S. Zhuo, T. Zhuang, et al., “YAP Inhibits ERα and ER+ Breast Cancer Growth by Disrupting a TEAD-ERα Signaling Axis,” Nature Communications 13, no. 1 (2022): 3075.

[182] Y. Gu, Y. Wang, Z. Sha, et al., “Transmembrane Protein KIRREL1 Regulates Hippo Signaling via a Feedback Loop and Represents a Therapeutic Target in YAP/TAZ-Active Cancers,” Cell Reports 40, no. 9 (2022): 111296.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.